1. HBW Insight
  2. >>Health
  3. >>Policy & Regulation
  4. >>Regulation

Latest Home-Use COVID-19 Sample Collection Kit Authorized In US Is First Available OTC

 
• By Reed Miller

Pixel kit allows users to send nasal swab samples to be tested with LabCorp’s a real-time reverse transcription polymerase chain reaction test. Health care providers will call consumers who test positive;  negative test results will be delivered by email or through LabCorp’s online portal.

Riga, Latvia - April 8 2020: Coronavirus SARS-CoV-2 testing at home. COVID-19 Rapid test cassette for coronavirus. Man holding a rapid testing kits. Man reading a manual how to do a Test at home

LabCorp's Pixel home-use test is the first COVID-19 test sample collection kit available OTC in the US following the Food and Drug Administration's emergency use authorization granted on 9 December.

The Pixel kit allows adults to self-collect a nasal swab sample at home and send it to LabCorp to be...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

German Switch Committee Supports OTC Melatonin And Acyclovir, Rejects Rupatadine

 
• By David Ridley

Germany’s Expert Committee for Prescription supports the Rx-to-OTC switches of melatonin and buccal acyclovir but rejects rupatadine.

Green Regulation Is ‘A Baseline Not A Burden’ – Behind Opella’s B Corp Journey

 
• By David Ridley

“For us, regulation is the floor, not the ceiling,” Opella's chief sustainability officer Marissa Saretsky tells HBW Insight as the firm gains B Corp Certification. Other topics covered in this exclusive interview include Opella's position on the revised Urban Wastewater Treatment Directive.

US FDA: No Replacement Yet For Animal Methods In Testing Systemic Effects Of Sunscreens

 
• By Lauren Nardella

While FDA fully supports the recent roadmap to reduce and eliminate animal testing, animal tests are still necessary for assessing systemic effects, says Jacqueline Corrigan-Curay, acting director for CDER, during a House Energy and Commerce Health Subcommittee hearing.

More from Policy & Regulation

Green Regulation Is ‘A Baseline Not A Burden’ – Behind Opella’s B Corp Journey

 
• By David Ridley

“For us, regulation is the floor, not the ceiling,” Opella's chief sustainability officer Marissa Saretsky tells HBW Insight as the firm gains B Corp Certification. Other topics covered in this exclusive interview include Opella's position on the revised Urban Wastewater Treatment Directive.

FDA Warns Whoop BPI App Is Unauthorized Device; Firm Says Wearable Is A Wellness Tool

 
• By Brian Bossetta

Recent FDA warning letter claims Boston firm specializing in wearable technology marketed a blood pressure device without agency approval, but the company rejects the assertion and says the agency is out of step with federal regulations.

Questions For FDA On OTC Switches, Alternative Tests And Budget Cuts At OMUFA Hearing

 
• By Malcolm Spicer

Texas Democrat Lizzie Fletcher didn’t pose questions for witnesses at House Health Subcommittee hearing but used her floor time to question whether Congress will keep federal agencies afloat. “I have real concerns that even if we reauthorize these programs, we won't have the funding or the staff to